Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

50%

Ph phase_1

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 1Safety & dosage

2(50.0%)

Phase 2Efficacy & side effects

2(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (50.0%)

Phase 22 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials

Showing 4 of 4

completedphase_2

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

NCT00813163

completedphase_1

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

NCT00940758

completedphase_1

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

NCT02884128

completedphase_2

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT00813072

Clinical Trials (4)

Showing 4 of 4 trials

NCT00813163Phase 2

Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

Completed

NCT00940758Phase 1

Phase I and Pharmacokinetic Study of Biweekly PEP02 in mCRC Refractory to 1st-line Oxaliplatin Base Therapy

Completed

NCT02884128Phase 1

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

Completed

NCT00813072Phase 2

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4